Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.47 AUD
Change Today -0.015 / -3.12%
Volume 169.3K
BNO On Other Exchanges
As of 1:10 AM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

bionomics ltd (BNO) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/6/14 - A$0.65
52 Week Low
02/13/15 - A$0.38
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIONOMICS LTD (BNO)

Related News

No related news articles were found.

bionomics ltd (BNO) Related Businessweek News

No Related Businessweek News Found

bionomics ltd (BNO) Details

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company’s product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trials and Phase I multiple ascending dose trials for the treatment of generalized anxiety disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in alzheimers's disease; BNC101, a monoclonal antibody, which has completed preclinical studies that targets cancer stem cells; and BNC105, a novel compound to disrupt the blood vessels that nourish tumors in cancer treatment. It also offers contract research services. The company has collaboration agreement with Merck & Co. to develop compounds targeting cognitive impairment in conditions, such as ADHD, alzheimer’s disease, parkinson’s disease, and schizophrenia. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.

Founded in 1998

bionomics ltd (BNO) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$483.8K
Chief Financial Officer
Total Annual Compensation: A$165.7K
Chief Medical Officer
Total Annual Compensation: A$433.5K
Legal Counsel and Company Secretary
Total Annual Compensation: A$45.8K
Chief Scientific Officer
Total Annual Compensation: A$47.2K
Compensation as of Fiscal Year 2015.

bionomics ltd (BNO) Key Developments

Bionomics Limited Appoints Alan W. Dunton as Non-Executive Director

Bionomics Limited has appointed Dr. Alan W. Dunton to the company's Board of Directors as a non-executive director. He served as President and Managing Director of the Janssen Research Foundation. Subsequently Dr. Dunton served as President and Chief Executive Officer at Metaphore Pharmaceuticals and at Panacos Pharmaceuticals. He is currently serves as a Director of Palatin Technologies, Oragenics and Sancilio Pharma.

Bionomics Limited Reports Data from Phase 1 Multiple Ascending Dose Trial of BNC210 for Anxiety and Depression

Bionomics Limited reported positive data from the completed Phase 1 multiple ascending dose, placebo controlled clinical trial of BNC210, an orally administered negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor (alpha-7 receptor) being developed for the treatment of anxiety and depression. The results showed that BNC210 was safe and well-tolerated, and consistent with its mechanism of action at the a7 receptor, showed that BNC210 significantly reduced the effect of nicotine as measured by electrocephalogram (EEG). In the study, a total of 54 healthy volunteers were enrolled and dosed for eight consecutive days, with 42 subjects receiving BNC210 (300mg - 2,000mg total dose per day) and 12 placebo. In addition to detailed safety evaluations, all study subjects underwent a standard battery of assessments measuring cognitive parameters. Subjective feelings produced by BNC210 were also assessed. Study results showed BNC210 was safe and well tolerated at all dose levels, and a maximum tolerated dose was not reached. No subject discontinued due to treatment-emergent adverse events. BNC210 administration did not result in adverse changes in cognition. The Bond & Lader Visual Analog Scales showed that there were no adverse changes in subjects' ratings of subjective feelings around alertness, contentedness or calmness and the Addiction Research Centre Inventory 49 check-list (ARCI49) indicated that BNC210 administration did not result in feelings associated with drugs of abuse. An additional pharmacodynamic test, the nicotine shift assay, was performed in subjects receiving either the higher dose of BNC210 or placebo. Subjects, all non-smokers, were administered nicotine by nasal spray with responses measured by EEG. Of the 30 subjects administered with nicotine prior to administration of either BNC210 or placebo, 13 responded to nicotine in a dose dependent manner. These nicotine responders were selected for analysis. When the study was unblinded, twelve of the nicotine responders received BNC210 whilst one nicotine responder received placebo. Eleven BNC210-treated subjects showed evidence of reduction in nicotine-induced EEG measures relative to relative to baseline whilst one BNC210- treated subject and the placebo-treated subject showed no changes in nicotine-induced EEG measures. Overall BNC210 treatment significantly reduced EEG changes induced by half milligram incremental doses of nicotine from 0.5 to 2 mg (p<0.02 - 0.0009).

Bionomics Ltd. Presents at Rodman & Renshaw 17th Annual Global Investment Conference, Sep-10-2015 02:35 PM

Bionomics Ltd. Presents at Rodman & Renshaw 17th Annual Global Investment Conference, Sep-10-2015 02:35 PM. Venue: The St. Regis Hotel, Two East 55th Street, New York, NY 10022, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BNO:AU A$0.47 AUD -0.015

BNO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BNO.
View Industry Companies

Industry Analysis


Industry Average

Valuation BNO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.1x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIONOMICS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at